-
1 Comment
Bioxyne Limited is currently in a long term uptrend where the price is trading 92.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Bioxyne Limited's total revenue sank by 10.4% to $1M since the same quarter in the previous year.
Its net income has dropped by 121.3% to $-432K since the same quarter in the previous year.
Finally, its free cash flow fell by 27.4% to $77K since the same quarter in the previous year.
Based on the above factors, Bioxyne Limited gets an overall score of 2/5.
| Exchange | AU |
|---|---|
| CurrencyCode | AUD |
| ISIN | AU000000BXN6 |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Market Cap | 45M |
|---|---|
| PE Ratio | 0.0 |
| Target Price | None |
| Beta | 0.12 |
| Dividend Yield | None |
Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. In addition, the company provides product research and development services, and telemedicine services. Further, it operates BLS Clinics, a telehealth platform; and CanXChange Australia, a machine-learning driven B2B technology platform for sponsors, manufacturers, cultivators, and pharmacies to interact, manage chain of custody, and buy and sell bulk starting materials, APIs, and finished products in a regulated environment. The company offers its products under the Dr Watson, Mirai Solution, and Apothecary CBD brands. It provides its products online, as well as through wholesale and direct sales in Australia, the United States, the United Kingdom, Japan, Czechia, Switzerland, France, and Germany. The company was incorporated in 1998 and is headquartered in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BXN.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
